Legacy Wealth Asset Management LLC Has $3.17 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Legacy Wealth Asset Management LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 6.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,575 shares of the company’s stock after selling 230 shares during the quarter. Eli Lilly and Company accounts for 0.8% of Legacy Wealth Asset Management LLC’s holdings, making the stock its 14th biggest position. Legacy Wealth Asset Management LLC’s holdings in Eli Lilly and Company were worth $3,167,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Private Ocean LLC increased its stake in Eli Lilly and Company by 8.2% in the 1st quarter. Private Ocean LLC now owns 1,092 shares of the company’s stock valued at $850,000 after buying an additional 83 shares during the last quarter. Vicus Capital increased its position in shares of Eli Lilly and Company by 57.4% in the first quarter. Vicus Capital now owns 861 shares of the company’s stock valued at $670,000 after acquiring an additional 314 shares during the last quarter. Brown Miller Wealth Management LLC bought a new stake in Eli Lilly and Company during the first quarter worth about $243,000. Fox Hill Wealth Management boosted its position in Eli Lilly and Company by 4.9% during the first quarter. Fox Hill Wealth Management now owns 10,540 shares of the company’s stock valued at $8,200,000 after purchasing an additional 492 shares during the last quarter. Finally, Foguth Wealth Management LLC. bought a new position in Eli Lilly and Company in the first quarter valued at approximately $482,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $892.70 on Friday. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The stock has a market capitalization of $848.45 billion, a price-to-earnings ratio of 109.94, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The company has a 50-day simple moving average of $919.74 and a two-hundred day simple moving average of $862.48.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Analysts forecast that Eli Lilly and Company will post 14.05 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LLY. Berenberg Bank upped their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Barclays upped their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Sanford C. Bernstein initiated coverage on shares of Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price objective for the company. Truist Financial upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Finally, Citigroup lifted their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,013.41.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.